WallStSmart

Lineage Cell Therapeutics Inc (LCTX)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 16930% more annual revenue ($2.23B vs $13.08M). MRNA leads profitability with a -141.4% profit margin vs -246.6%. MRNA earns a higher WallStSmart Score of 21/100 (F).

LCTX

Avoid

18

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.7Quality: 6.5
Piotroski: 3/9Altman Z: -6.81

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LCTXUndervalued (+84.3%)

Margin of Safety

+84.3%

Fair Value

$11.43

Current Price

$1.03

$10.40 discount

UndervaluedFair: $11.43Overvalued
MRNAUndervalued (+69.9%)

Margin of Safety

+69.9%

Fair Value

$134.69

Current Price

$154.04

$19.35 discount

UndervaluedFair: $134.69Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LCTX1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

LCTX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$268.08M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
10.642/10

Expensive relative to growth rate

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
9.1x4/10

Trading at 9.1x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : LCTX

The strongest argument for LCTX centers on Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : LCTX

The primary concerns for LCTX are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

LCTX carries more volatility with a beta of 1.55 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

LCTX generates stronger free cash flow (-7M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRNA scores higher overall (21/100 vs 18/100). LCTX offers better value entry with a 84.3% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage Cell Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.

Visit Website →

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?